Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01787487 |
|
Recruitment Status :
Recruiting
First Posted : February 8, 2013
Last Update Posted : August 22, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Myelofibrosis Transformation in Essential Thrombocythemia Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Primary Myelofibrosis | Drug: Azacitidine Other: Laboratory Biomarker Analysis Drug: Ruxolitinib Phosphate | Phase 2 |
PRIMARY OBJECTIVES:
I. To determine the efficacy of the combination of RUX (ruxolitinib phosphate) with AZA (azacytidine) in patients with myelofibrosis (MF) (primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocythemia myelofibrosis [PMF, post- PV MF, or post - ET MF]) in achieving objective improvements in disease status.
II. To determine the efficacy of the combination of RUX + AZA in patients with myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (breakpoint cluster region [BCR]-c-abl oncogene 1, non-receptor tyrosine kinase [ABL1] negative: aCML), and myelodysplastic syndromes/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U), in achieving objective improvements in disease status.
SECONDARY OBJECTIVES:
I. To determine the safety of the RUX + AZA combination in patients with MF and MDS/MPN.
TERTIARY OBJECTIVES:
I. To explore time to response (TTR) and duration of response (DOR). II. To explore the effect of the combination on anemia and transfusion dependence in patients with MF and MDS/MPN.
III. To explore the impact of baseline mutational profile on International Working Group (IWG)-Myeloproliferative Neoplasms Research and Treatment (MRT) response and overall survival in patients with MF and MDS/MPN.
IV. To explore the impact of baseline anemia on overall survival in patients with MF and MDS/MPN.
OUTLINE: Patients are assigned to 1 of 2 treatment arms.
ARM I (MF): Patients with MF receive ruxolitinib phosphate orally (PO) twice daily (BID) on days 1-28. Beginning course 4, patients also receive azacytidine subcutaneously (SC) or intravenously (IV) for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
ARM II (MDS/MPN): Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.
After completion of study treatment, patients are followed up for 30 days and up to 5 years.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 125 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm |
| Actual Study Start Date : | March 13, 2013 |
| Estimated Primary Completion Date : | March 1, 2023 |
| Estimated Study Completion Date : | March 1, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm I (MF patients)
Patients with MF receive ruxolitinib phosphate PO BID on days 1-28. Beginning course 4, patients also receive azacytidine SC or IV for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: Azacitidine
Given SC or IV
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Drug: Ruxolitinib Phosphate Given PO
Other Names:
|
|
Experimental: Arm II (MDS/MPN patients)
Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.
|
Drug: Azacitidine
Given SC or IV
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Drug: Ruxolitinib Phosphate Given PO
Other Names:
|
- Objective response rate (complete remission, partial remission, clinical improvement) in patients with myelofibrosis [ Time Frame: Up to 24 weeks ]The method of Thall, Simon and Estey will be used for futility monitoring for this study. The objective response rate will be estimated along with the Bayesian 95% credible interval.
- Objective response rate (complete remission, partial remission, and hematologic improvement) in patients with myelodysplastic syndromes/myeloproliferative neoplasms [ Time Frame: Up to 24 weeks ]The method of Thall, Simon and Estey will be used for futility monitoring for this study.
- Incidence of adverse events defined as grade 3-4 clinically relevant non-hematologic toxicity or a serious adverse event that is felt to be drug related as assessed by the Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 30 days after completion of study treatment ]The method of Thall, Simon and Estey will be used for toxicity monitoring for this study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with a diagnosis of primary myelofibrosis (PM), post polycythemia vera myelofibrosis (PPV MF), or post essential thrombocythemia myelofibrosis (PET MF) requiring therapy, including those previously treated and relapsed or refractory, or if newly diagnosed, with intermediate or high risk according to International Working Group (IWG-MRT) criteria
- Patients with a diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) that require therapy
- Understanding and voluntarily signing an Institutional Review Board (IRB)-approved informed consent form
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Direct bilirubin of =< 2 mg/dL
- Serum glutamate pyruvate transaminase (SGPT) =< 2.5 x upper limit of normal (ULN) or 5 x ULN if related to MF or MDS/MPN associated liver infiltration
- If total bilirubin is =< 2, fractionation is not required for eligibility determination
- Creatinine =< 2.5 mg/dL
- Platelets >= 50 x 10^9/L
- Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
Exclusion Criteria:
- For the MF and MDS/MPN-U arms (arms 1 & 2), use of any other standard drug (except hydroxyurea, anagrelide, growth factors, Revlimid, clofarabine, etc) or experimental drug or therapy within 14 days of starting study therapy
- Patients previously treated with RUX or AZA (only applicable for the MF and MDS/MPN arms)
- Any serious psychological condition or psychiatric illness that would prevent the subject from signing the informed consent document, in the investigator opinion
- Pregnant or lactating females
- Subjects of childbearing potential who are unwilling to take appropriate precautions (from screening through follow-up) to avoid becoming pregnant or fathering a child; females of non-childbearing potential are defined as women who a) are 55 years of age with history of amenorrhea for 1 year OR b) are surgically sterile for at least 3 months; for females of childbearing potential, or for males, pregnancy must be avoided by taking appropriate precautions; these precautions and the methods of contraception should be communicated to the subjects and their understanding confirmed
- Any condition which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- Known positive for human immunodeficiency virus (HIV) or with known active infectious hepatitis, type A, B or C
- Patients with active malignancy of other type than required for this study, are not eligible with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast; patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01787487
| Contact: Naval Daver | 713-794-4392 | ndaver@mdanderson.org |
| United States, Texas | |
| M D Anderson Cancer Center | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Naval Daver 713-794-4392 | |
| Principal Investigator: Naval Daver | |
| Principal Investigator: | Naval Daver | M.D. Anderson Cancer Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01787487 |
| Other Study ID Numbers: |
2012-0737 NCI-2013-00704 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2012-0737 ( Other Identifier: M D Anderson Cancer Center ) P30CA016672 ( U.S. NIH Grant/Contract ) |
| First Posted: | February 8, 2013 Key Record Dates |
| Last Update Posted: | August 22, 2022 |
| Last Verified: | August 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Neoplasms Myeloproliferative Disorders Myelodysplastic-Myeloproliferative Diseases Bone Marrow Neoplasms Hematologic Neoplasms Neoplasms by Site Polycythemia Vera Myelodysplastic Syndromes Primary Myelofibrosis Polycythemia Thrombocytosis Thrombocythemia, Essential |
Bone Marrow Diseases Hematologic Diseases Blood Platelet Disorders Blood Coagulation Disorders Hemorrhagic Disorders Azacitidine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |